Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Arcus Biosciences Q1 2026 Earnings Call - Casdatifan Takes Center Stage in Kidney Cancer Push
Arcus Biosciences is pivoting hard into a new era of fully owned, late-stage development with casdatifan as the undisputed centerpiece. The company is accelerating enrollment in its phase III PEAK-1 k...
- 1. Full ownership of casdatifan marks a strategic inflection point for Arcus, eliminating partnership dependencies and allowing full control over development and commercialization.
- 2. Phase III PEAK-1 enrollment is accelerating and on track to complete by year-end 2026, targeting the IO-experienced second-line setting with a clear path to establish casdatifan plus cabozantinib as the new standard of care.
- 3. Management emphasizes casdatifan’s superior pharmacodynamic profile over belzutifan, citing sustained HIF-2 inhibition that translates to longer progression-free survival and higher response rates.
- +9 more takeaways
DHI Group Q1 2026 Earnings Call - ClearanceJobs Growth Offsets Tech Hiring Slowdown
DHI Group reported a mixed but strategically focused first quarter for 2026. ClearanceJobs drove the headline performance with 5% revenue growth and 7% bookings growth, buoyed by a $1 trillion U.S. de...
- ClearanceJobs revenue grew 5% year-over-year to $14.0 million, while bookings increased 7% to $18.0 million, highlighting the platform's role as the company's primary growth engine.
- The acquisition of Point Solutions Group (PSG) contributed $700,000 in revenue and bookings in its first partial quarter, with management projecting a full-year revenue uplift of approximately $6 million.
- Defense budget tailwinds are accelerating; the $1 trillion U.S. defense budget and NATO's 5% GDP spending targets are driving improved customer sentiment and demand for cleared tech talent.
- +7 more takeaways
Solventum Technologies Q1 2026 Earnings Call - Momentum and Margin Expansion Outpace Separation Headwinds
Solventum kicked off fiscal 2026 with a quarter that defied the noise. The company delivered organic sales growth and EPS that beat both plan and consensus, proving that the commercial engine is firin...
- Organic sales grew 2.1% in Q1 2026, beating expectations and setting a strong tone for the full year.
- EPS came in at $1.48, representing 11% growth and landing ahead of consensus.
- Gross margins expanded by 80 basis points year-over-year to 56.4%, driven by favorable mix, sales leverage, and programmatic savings.
- +7 more takeaways
Rapid7 Q1 2026 Earnings Call - AI-Driven Security Shift Fuels Core Platform Growth
Rapid7 delivered outperformance across all guided metrics in Q1 2026, with ARR of $832 million and non-GAAP operating income of $24 million, driven by sustained growth in its core Detection and Respon...
- Rapid7 exceeded Q1 2026 guidance, reporting $832 million in ARR and $24 million in non-GAAP operating income, with strong free cash flow of $33 million.
- Core platform solutions (D&R and Exposure Management) now represent over 80% of ARR, with D&R growth accelerating to 7% year-over-year, driven by MDR strength.
- The acquisition of Kenzo Security introduces an agentic AI platform that automates security operations, shifting focus from manual alert investigation to machine-speed remediation at scale.
- +7 more takeaways
Myriad Genetics Q1 2026 Earnings Call - Hereditary Cancer Growth Fuels Confidence as MRD and FirstGene Launches Set Stage for 2026 Acceleration
Myriad Genetics reported Q1 2026 revenue of $200.4 million, landing in line with guidance, driven by double-digit volume growth in hereditary cancer testing and strong momentum in its mental health fr...
- Q1 2026 revenue came in at $200.4 million, within the low end of the $200-$202 million guidance range, representing 2% year-over-year growth.
- Hereditary cancer testing volume surged 14% year-over-year, with the unaffected population growing 16% and the affected population growing 10%, outpacing market rates.
- GeneSight mental health test revenue jumped 24% year-over-year to $38.3 million, supported by 7% volume growth and improved reimbursement dynamics from biomarker legislation.
- +7 more takeaways
Dentsply Sirona Q1 2026 Earnings Call - Return to Growth Plan Faces Headwinds Amid Tariffs and Execution Shifts
Dentsply Sirona reported Q1 2026 revenue of $880 million, essentially flat on a reported basis but down 6.7% on a constant currency basis. The decline was driven by tough comps, tariff impacts, and a ...
- Q1 2026 revenue came in at $880 million, up 0.1% as reported but down 6.7% on a constant currency basis, reflecting tough comps, tariff headwinds, and a one-time institutional installation in the prior year.
- Adjusted EBITDA margins contracted 430 basis points, driven by a 560 basis point gross margin decline from lower volumes, unfavorable sales mix, and tariff impacts.
- Operating expenses fell by $20 million on a constant currency basis, signaling early progress in the Return to Growth action plan’s cost restructuring efforts.
- +7 more takeaways
Talen Energy Q1 2026 Earnings Call - Cornerstone Acquisition Financing Locked In, 2027/2028 FCF Per Share Outlook Raised
Talen Energy reported a strong first quarter of 2026, with adjusted EBITDA more than doubling and adjusted free cash flow quadrupling year-over-year, driven by the recent acquisition of Freedom and Gu...
- Q1 2026 Adjusted EBITDA reached $473 million and adjusted free cash flow hit $350 million, with year-over-year growth more than doubling and quadrupling respectively, driven by the Freedom and Guernsey acquisitions and higher market prices.
- Talen Energy secured $4 billion in senior unsecured notes for the pending Cornerstone acquisition, reducing the cost of capital and allowing the company to close the deal once regulatory approvals are finalized.
- The company reaffirmed its 2026 guidance, with adjusted EBITDA expected between $1.75 billion and $2.05 billion and adjusted free cash flow between $980 million and $1.18 billion, excluding Cornerstone.
- +7 more takeaways
GRAIL Q1 2026 Earnings Call - Galleri Volume Surges 50% Amid Epic Integration and ASCO Data Anticipation
GRAIL reported strong first quarter 2026 results, with Galleri test volumes jumping 50% year-over-year to over 56,000 tests and screening revenue climbing 37% to $39.8 million. The company continues t...
- Galleri test volumes surged 50% year-over-year in Q1 2026, surpassing 56,000 tests, while screening revenue grew 37% to $39.8 million.
- Total revenue reached $40.8 million, up 28% year-over-year, driven by a 37% increase in screening revenue and $1 million in development services.
- Net loss improved 12% to $93.2 million, with adjusted EBITDA narrowing 19% to negative $79.9 million, reflecting improved operational leverage.
- +7 more takeaways
"Hinge Health" Q1 2026 Earnings Call - Strong Q1 Results, Raised Guidance, and Migraine Program Launch
Hinge Health delivered a strong start to 2026, with Q1 revenue of $182 million, up 47% year-over-year, significantly beating guidance. The company raised its full-year revenue guidance to $798-$804 mi...
- Revenue of $182 million in Q1 2026, up 47% year-over-year, significantly exceeding the guidance range of $171-$173 million.
- LTM calculated billings reached $770 million, a 52% year-over-year increase, driven by higher eligible lives and improved member yields.
- Gross margin expanded to 85% from 81% in Q1 2025, reflecting AI-driven care team efficiency and hardware optimization.
- +12 more takeaways
Energy Vault Q1 2026 Earnings Call - Backlog Surges to $1.35 Billion as Shift to IPP Model Accelerates
Energy Vault delivered a 156% year-over-year revenue increase in Q1 2026, driven by a decisive pivot from project-based energy storage sales to a vertically integrated, build-own-operate infrastructur...
- Record backlog growth: Contracted backlog surged 108% year-over-year to $1.35 billion, with over 80% now tied to own-and-operate assets, signaling a successful transition from episodic project revenue to long-term infrastructure cash flows.
- Revenue acceleration: Q1 2026 revenue jumped 156% year-over-year to $21.9 million, driven by higher energy storage deliveries and initial contributions from the Asset Vault portfolio.
- Asset base expansion: Total megawatts under control, construction, or operation exceeded 1 GW, nearly five times year-over-year, providing a foundation for recurring revenue as projects reach commercial operation.
- +7 more takeaways